Chemical compound
Pharmaceutical compound
VK2809 Clinical data Other names VK-2809; MB07811 Identifiers (2R ,4S )-4-(3-Chlorophenyl)-2-[(4-{[4-hydroxy-3-(propan-2-yl)phenyl]methyl}-3,5-dimethylphenoxy)methyl]-1,3,2λ5 -dioxaphosphinan-2-one
CAS Number DrugBank UNII CompTox Dashboard (EPA) Chemical and physical data Formula C 28 H 32 Cl O 5 P Molar mass −1
VK2809 (formerly known asMB07811 ) is athyromimetic prodrug whose active form is selective for theTHR-β isoform. It is being developed byViking Therapeutics in a phase II trial for the treatment ofnonalcoholic steatohepatitis [ 1] [ 2] glycogen storage disease type Ia .[ 3]
In 2023, Viking Therapeutics filed a lawsuit against the developer ofASC41 , Chinese company Ascletis BioScience, accusing it of stealing Viking's trade secrets to develop ASC41 which is allegedly similar to, or identical to, VK2809.[ 4] [ 5]
^ "VK2809" .Viking Therapeutics . Retrieved15 September 2023 .^ Alkhouri, Naim (1 February 2020)."Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)" .Expert Opinion on Investigational Drugs .29 (2):99– 101.doi :10.1080/13543784.2020.1708899 ISSN 1354-3784 .PMID 31868036 . ^ Zhou, Jin; Waskowicz, Lauren R.; Lim, Andrea; Liao, Xiao-Hui; Lian, Brian; Masamune, Hiroko; Refetoff, Samuel; Tran, Brian; Koeberl, Dwight D.; Yen, Paul M. (1 August 2019)."A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia" .Thyroid .29 (8):1158– 1167.doi :10.1089/thy.2019.0007 .ISSN 1050-7256 .PMC 6707038 PMID 31337282 . ^ "Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache" .Fierce Biotech . 3 January 2023. Retrieved2 December 2023 .^ "Viking Therapeutics accuses competitor of pilfering proprietary information" .Chemical & Engineering News . January 9, 2023.Viking infers that ASC41 is Ascletis's version of—if not the same compound as—VK2809 
